Foreign Matter Analysis

Offering a comprehensive range of testing and consulting services.

Resolian specializes in foreign matter investigations across several industries, including pharmaceutical/biopharmaceutical, veterinary medicine, consumer healthcare, medical devices, catalysts, agrochemicals, and cosmetics.

Resolian provides a comprehensive range of testing and consulting services to solve your specific challenges at any stage of your product lifecycle. These services can help you to:

  • Protect your patients from the risks of contaminated products
  • Ensure regulatory compliance
  • Maintain product quality
  • Achieve batch consistency
  • Improve cost efficiency
  • Protect your supply chain
  • Support your research and development efforts

Resolian has been audited by the FDA (US) and the MHRA (UK), and holds a controlled substance license from the Home Office, allowing for the handling and testing of all classes of controlled substances.

With a proven track record of success in helping manufacturers resolve FPM contamination issues, Resolian is committed to providing you the highest level of customer service in a timely manner.

Reach out to us directly to learn more about Resolian’s Foreign Matter Analysis services.

Types of FPM Identified

Resolian’s team of experts can identify and characterize a wide range of FPM, including:

  • Fibers
  • Metallic particles
  • Glass shards and delamination
  • Microplastics and polymers
  • Lubricant droplets
  • Corrosion products
  • Smears and stains
  • Residues and precipitates
  • Agglomeration

Our
Resources

Our Resources

Harmonizing Quality Standards Across Global Labs

Harmonizing Quality Standards Across Global Labs with David Butler

Globally Harmonized Labs

ELISpot-Antigen Specific Response Assays

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.